A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability.
Rawson, T.E., Ruth, M., Blackwood, E., Burdick, D., Corson, L., Dotson, J., Drummond, J., Fields, C., Georges, G.J., Goller, B., Halladay, J., Hunsaker, T., Kleinheinz, T., Krell, H.W., Li, J., Liang, J., Limberg, A., McNutt, A., Moffat, J., Phillips, G., Ran, Y., Safina, B., Ultsch, M., Walker, L., Wiesmann, C., Zhang, B., Zhou, A., Zhu, B.Y., Ruger, P., Cochran, A.G.(2008) J Med Chem 51: 4465-4475
- PubMed: 18630890 
- DOI: https://doi.org/10.1021/jm800052b
- Primary Citation of Related Structures:  
3COH - PubMed Abstract: 
Aurora kinase inhibitors have attracted a great deal of interest as a new class of antimitotic agents. We report a novel class of Aurora inhibitors based on a pentacyclic scaffold. A prototype pentacyclic inhibitor 32 (AKI-001) derived from two early lead structures improves upon the best properties of each parent and compares favorably to a previously reported Aurora inhibitor, 39 (VX-680) ...